| Literature DB >> 15566589 |
Titia M Vriesendorp1, J Hans DeVries, Jan B F Hulscher, Frits Holleman, Jan J van Lanschot, Joost B L Hoekstra.
Abstract
INTRODUCTION: Treating hyperglycaemia in hospitalized patients has proven to be beneficial, particularly in those with obstructive vascular disease. In a cohort of patients undergoing resection for oesophageal carcinoma (a group of patients with severe surgical stress but a low prevalence of vascular disease), we investigated whether early postoperative hyperglycaemia is associated with increased incidence of infectious complications and prolonged in-hospital stay.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15566589 PMCID: PMC1065066 DOI: 10.1186/cc2970
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Other possible risk factors for infection and length of stay
| Preoperative parameter | Value | Missing values (%) |
| Age in years (mean ± SD) | 62.4 ± 10.0 | 0 |
| Male sex ( | 127 (84.1) | 0 |
| ASA | 0 | |
| Class I ( | 47 (31.1) | |
| Class II ( | 104 (68.9) | |
| History of cardiac valve disease or arrhythmia ( | 7 (4.6) | 0.7 |
| History of hypertension ( | 21 (13.9) | 0.7 |
| History of coronary artery disease ( | 16 (10.6) | 0.7 |
| BMI (mean ± SD) | 25.4 ± 3.3 | 25.8 |
| Percentage of expected FEV1 (mean ± SD) | 101 ± 18 | 18.5 |
| Diabetes mellitus ( | 9 (6.0) | 0.7 |
| Preoperative weight loss (kg; mean ± SD) | 5.3 ± 6.6 | 7.9 |
| Clinical staging of tumor | 1.3 | |
| Stage I ( | 18 (11.9) | |
| Stage II ( | 68 (45.0) | |
| Stage III ( | 58 (38.4) | |
| Stage IV ( | 5 (3.3) | |
| Allocated to transthoracic procedure ( | 78 (51.7%) | 0 |
| Duration of surgery (hours; mean ± SD) | 5.3 (1.6) | 0.7 |
| Insulin use within 48 hours after surgery ( | 9 (6.0%) | 9.2 |
A total of 151 patients were included. ASA, American Society of Anesthesiologists; BMI, body mass index; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
Figure 1Percentage of (a) infections and (b) median length of hospital stay per glucose quartile: first quartile 5.2–7.4 mmol/l, second quartile 7.5–8.2 mmol/l, third quartile 8.3–9.2 mmol/l, and fourth quartile 9.3–17.2 mmol/l. The error bars in panel b represent the interquartile range.
Multivariate analysis of infectious complications
| Prognostic variable | OR (95% CI) | |
| FEV1 (per 10% of expected FEV1) | 0.79 (0.63–0.99) | 0.045 |
| History of cardiac valve disease or arrhythmia | 7.30 (0.78–68.3) | 0.081 |
| Duration of surgery | 1.27 (0.98–1.64) | 0.069 |
| Age per 10 years | 1.36 (0.90–2.07) | 0.142 |
| Mean postoperative glucose | 1.21 (0.86–1.72) | 0.279 |
CI, confidence interval; FEV1, forced expiratory volume in 1 s; OR, odds ratio.
Multivariate analysis of length of stay
| Prognostic variable | ß | SE of ß | |
| Duration of surgery | 0.062 | 0.021 | 0.004 |
| BMI | 0.010 | 0.006 | 0.072 |
| Mean postoperative glucose | 0.024 | 0.018 | 0.195 |
| History of cardiac valve disease or arrhythmia | 0.058 | 0.091 | 0.527 |
| Transhiatal procedure | 0.034 | 0.065 | 0.599 |
BMI, body mass index; SE, standard error.